Marshall Financial Group LLC Purchases Shares of 31,997 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Marshall Financial Group LLC acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 31,997 shares of the biopharmaceutical company’s stock, valued at approximately $1,530,000.

Several other large investors have also modified their holdings of HALO. GAMMA Investing LLC increased its position in Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 350 shares during the last quarter. Toth Financial Advisory Corp purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at $57,000. FSC Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth $65,000. Park Place Capital Corp raised its position in shares of Halozyme Therapeutics by 828.1% in the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 1,209 shares during the period. Finally, CWM LLC boosted its holdings in Halozyme Therapeutics by 77.5% in the third quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 668 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Up 0.3 %

Shares of NASDAQ:HALO opened at $55.77 on Friday. The company’s fifty day moving average is $49.59 and its two-hundred day moving average is $54.22. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The stock has a market capitalization of $7.10 billion, a price-to-earnings ratio of 18.47, a price-to-earnings-growth ratio of 0.42 and a beta of 1.24.

Analysts Set New Price Targets

HALO has been the subject of several research analyst reports. JMP Securities upped their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. HC Wainwright increased their target price on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Wells Fargo & Company reduced their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Finally, Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $60.89.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.